Oncology Biosimilars Market Size, Share & Industry Analysis, By Drug Class (Anti-HER2 Monoclonal Antibodies, Anti-VEGF Monoclonal Antibodies, Anti-CD20, and Immune Checkpoint Inhibitors), By Product (Trastuzumab, Bevacizumab, Rituximab, Pertuzumab, and Pembrolizumab), By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Non-Hodgkin's Lymphoma, and Melanoma), By Age Group (Pediatric and Adults), By Route of Administration (Intravenous and Subcutaneous), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Retail Pharmacies), and Regional Forecast, 2026-2034

Last Updated: August 10, 2026 | Format: PDF | Report ID: FBI100578

Buy Now

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 14.73% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Region
By Drug Class	Anti-HER2 Monoclonal Antibodies Anti-VEGF Monoclonal Antibodies Anti-CD20 Monoclonal Antibodies Immune Checkpoint Inhibitor Biosimilars Other Therapeutic Monoclonal Antibodies Others
By Product	Trastuzumab Bevacizumab Rituximab Pertuzumab Pembrolizumab Nivolumab Ipilimumab Others
By Application	Breast Cancer Lung Cancer Colorectal Cancer Non-Hodgkin’s Lymphoma Chronic Lymphocytic Leukemia Gastric & Gastroesophageal Junction Cancer Melanoma Others
By Age Group	Pediatric Adults
By Route of Administration	Intravenous Subcutaneous Others
By Distribution Channel	Hospital Pharmacies Specialty Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies
By Region	North America (By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Country) U.S. Canada Europe (By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, Product, Application, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of the Middle East & Africa